Skip to Main content Skip to Navigation
Journal articles

Ixazomib in the management of relapsed multiple myeloma

Cyrille Touzeau 1 Philippe Moreau 2
1 CRCINA-ÉQUIPE 10 - Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
2 CRCINA-ÉQUIPE 11 - Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Abstract : The development of proteasome inhibitors contributed to the dramatic life expectancy improvement observed in myeloma patients over the past decades. Ixazomib is a boron-containing selective and reversible proteasome inhibitor that demonstrated antimyeloma activity with excellent safety profile. Ixazomib is the first orally available proteasome inhibitor approved in combination with lenalidomide and dexam-ethasone for the treatment of myeloma patients who received at least one prior therapy. The present review addresses the current knowledge regarding the clinical use of ixazomib in relapsed myeloma patients .
Document type :
Journal articles
Complete list of metadatas

Cited literature [32 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01934497
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, November 26, 2018 - 8:54:49 AM
Last modification on : Thursday, June 18, 2020 - 10:32:02 PM
Long-term archiving on: : Wednesday, February 27, 2019 - 12:54:04 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Cyrille Touzeau, Philippe Moreau. Ixazomib in the management of relapsed multiple myeloma. Future Oncology, Future Medicine, 2018, 14 (20), pp.2013 - 2020. ⟨10.2217/fon-2017-0710⟩. ⟨inserm-01934497⟩

Share

Metrics

Record views

187